VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX – Get Rating) in a report released on Thursday morning. The firm issued a sell rating on the stock.

VolitionRx Stock Performance

VolitionRx stock opened at $1.78 on Thursday. The stock’s 50-day moving average is $1.86 and its 200-day moving average is $1.94. The company has a market cap of $103.49 million, a price-to-earnings ratio of -3.24 and a beta of 1.73. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.04 and a quick ratio of 1.04. VolitionRx has a 12 month low of $1.31 and a 12 month high of $3.30.

About VolitionRx

(Get Rating)

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.